Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes
(1) Background: Over the past 20 years, monoclonal antibodies have been developed for the treatment of severe asthma, with numerous randomised controlled trials (RCTs) conducted to define their safety and efficacy. The growing availability of biologics, which until now have only been available for T...
Main Author: | Francesco Menzella |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/4/1546 |
Similar Items
-
Switching Biological Therapies in Severe Asthma
by: Giulia Scioscia, et al.
Published: (2023-05-01) -
Personalized Medicine in Severe Asthma: From Biomarkers to Biologics
by: Chun-Yu Chen, et al.
Published: (2023-12-01) -
Severe Asthma and Biological Therapies: Now and the Future
by: Olaia Sardon-Prado, et al.
Published: (2023-09-01) -
Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
by: Davidescu L, et al.
Published: (2022-06-01) -
Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review
by: Tommaso Pianigiani, et al.
Published: (2023-02-01)